Evaluation of biocatalyzed cannabionoid extracts

植物大麻素由于其作为多种疾病的治疗剂的潜力而受到相当大的关注。虽然它们是天然存在的，但CMH Biotechnologies Inc.已申请专利的过程中的生物催化大麻素使用单细胞生物体，从而产生大量的这些大麻素在相对较高的纯度，可用于分析参考材料和作为药用级大麻素。已观察到生物合成是非特异性的，产生许多次要大麻素。该基金的目的是评估这些在生物合成途径中产生的低水平代谢物的结构，并确定它们是否是天然存在的或具有潜在治疗活性的新型化合物。这种伙伴关系将联合收割机结合生物技术和先进的分析化学，以更好地了解对大麻素生物催化的影响。

Phytocannabinoids have received considerable attention due to their potential as therapeutic agents for a widevariety of ailments. Although they are naturally occurring, CMH Biotechnologies Inc. has patented the processof biocatalysis of cannabinoids using single-celled organisms, thereby producing large amounts of thesecannabinoids in relatively high purity, which can be used for analytical reference materials and aspharmaceutical grade cannabinoids. The biosynthesis has been observed to be non-specific with many minorcannabinoids being produced. The purpose of this Engage grant is to evaluate the structures of these low-levelmetabolites being produced in the biosynthetic pathways and establish whether they are naturally occurring ornovel compounds with potential therapeutic activity. This partnership will combine biotechnology andadvanced analytical chemistry for a better understanding of the impacts on cannabinoid biocatalysis.